Impact of Shenfu Injection（参附注射液） Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure

YAO Kuiwu; CHEN Mengqian; LIU Tiantian; LIU Zhangjing; WANG Xin; GUO Yu; JIANG Min; WANG Zhanrong; FENG Xingzhong; ZHANG Liangdeng

doi:10.13288/j.11-2166/r.2016.24.012

您当前的位置：

首页 >

文章列表页 >

Impact of Shenfu Injection（参附注射液） Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure

更新时间：2021-11-17

- Impact of Shenfu Injection（参附注射液） Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure
- Journal of Traditional Chinese Medicine Vol. 57, Issue 24, Pages: 2117-2120(2016)
- 作者机构：
  
  1. 中国中医科学院广安门医院
  2. 首都医科大学
  3. 中国中医科学院望京医院
  4. 北京中医药大学
  5. 首都医科大学附属北京世纪坛医院
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2016.24.012
  CLC： R541.4;R541.6
- Published：2016
- 稿件说明：
移动端阅览
[1]姚魁武,陈孟倩,刘甜甜,刘张静,王欣,郭宇,姜敏,王占荣,冯兴中,张良登.参附注射液辅助治疗对冠心病慢性心力衰竭患者生活质量及生存情况的影响[J].中医杂志,2016,57(24):2117-2120.

YAO Kuiwu, CHEN Mengqian, LIU Tiantian, et al. Impact of Shenfu Injection（参附注射液） Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure[J]. Journal of Traditional Chinese Medicine2016, 57(24): 2117-2120.
[1]姚魁武,陈孟倩,刘甜甜,刘张静,王欣,郭宇,姜敏,王占荣,冯兴中,张良登.参附注射液辅助治疗对冠心病慢性心力衰竭患者生活质量及生存情况的影响[J].中医杂志,2016,57(24):2117-2120. DOI： 10.13288/j.11-2166/r.2016.24.012.

YAO Kuiwu, CHEN Mengqian, LIU Tiantian, et al. Impact of Shenfu Injection（参附注射液） Adjunctive Therapy on Quality of Life and Survival Condition of Patients with Coronary Heart Disease with Chronic Heart Failure[J]. Journal of Traditional Chinese Medicine2016, 57(24): 2117-2120. DOI： 10.13288/j.11-2166/r.2016.24.012.

摘要

目的观察参附注射液辅助常规西药治疗冠心病慢性心力衰竭的临床疗效。方法将102例冠心病慢性心力衰竭心肾阳虚证患者随机分为治疗组与对照组各51例。对照组予西医常规治疗

治疗组予参附注射液40 ml/d静脉滴注辅助西医常规治疗

分别在治疗前及治疗2周应用明尼苏达心力衰竭生活质量调查表（LHFQ）进行生活质量评价

并于治疗前、治疗1周与2周分别进行中医证候评分

以电话或门诊方式随访进行生存情况分析。结果治疗组治疗2周后中医证候疗效显效19例

有效22例

无效6例

恶化4例

总有效率80.39%;对照组分别为13例、21例、10例、7例及66.67%

两组比较治疗组优于对照组（P<0.05）。两组治疗2周LHFQ总分均较本组治疗前下降（P<0.05）。两组治疗1周、2周中医证候总积分均较本组治疗前下降（P<0.05）

治疗2周治疗组中医证候总积分均低于同时间点对照组（P<0.05）。治疗组生存率为96.1%高于对照组的82.4%（P<0.05）。结论参附注射液辅助西药常规治疗冠心病慢性心力衰竭可提高临床疗效及生存时间

改善临床症状及生活质量。

Abstract

Objective To examine the clinical effect of Shenfu Injection assisting routine western drug to treat coronary heart disease with chronic heart failure. Methods Totally 102 cases of coronary heart disease with chronic heart failure with syndrome of Yang deficiency of heart and kidney were randomized into a treatment group（ 51 cases）and a control group（ 51 cases）. The control group was given western medicine routine therapy. The treatment group was given Shenfu Injection 40 ml / d intravenous drip to assist western medicine routine therapy. The Minnesota Living with Heart Failure questionnaire（ MLHFQ） was applied to evaluate quality of life before and 2 weeks after treatment.Chinese medicine syndrome score was rated before

and 1 week and 2 weeks after treatment. Survival condition analysis was made by telephone or during outpatient follow-up. Results After 2 weeks of treatment

as for Chinese medicine syndrome effect

there were 19 cases markedly improved

22 improved

6 invalid

and 4 getting worse in the treatment group

with the total effective rate of 80. 39%. In the control group

there were 13 cases markedly improved

21 improved

10 invalid

and 7 getting worse

with the total effective rate of 66. 67%. The treatment group was superior to the control group（ P < 0. 05）. The total score of MLHFQ in both groups decreased 2 weeks after treatment（ P < 0. 05）. The total score of Chinese medicine syndrome in both groups decreased one and 2 weeks after treatment（ P < 0. 05）. The total score of Chinese medicine syndrome in the treatment group 2 weeks after treatment was lower than that in the control group at the same time point（ P < 0. 05）. The survival rate of the treatment group was 96. 1%

higher than 82. 4% in the control group（ P < 0. 05）. Conclusion Shenfu Injection assisting western drug routine therapy might enhance the clinical effect

extend survival time

relieve clinical symptoms

and improve quality of life in the treatment of coronary heart disease with chronic heart failure.

关键词

Keywords

references

查看原文

Views

510

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Optimized New Shengmai Powder （优化新生脉散方） on Exercise Tolerance in Patients with Chronic Heart Failure of Qi Deficiency，Blood Stasis and Fluid Retention Syndrome：A Randomized，Double-Blind，Placebo-Controlled Trial

Effect of Jiuxin Pill （救心丸）on Exercise Tolerance and Quality of Life in Patients of Stable Angina Pectoris：A Randomized，Double-Blind，Placebo-Controlled，Multi-Center Clinical Trial

Cohort Study on the Prevention and Treatment of Chronic Heart Failure with Yang Qi Deficiency, Blood Stasis and Water Retention Syndrome by Acupoint Application in Dog Days

Effects of Modified Shuanghe Powder （双和散） Combined with Yangxin Guiding Exercise on Coronary Heart Disease with Anxiety and Depression

Adjuvant Therapy with Fulvning Granule（复律宁颗粒） in Treating 30 Cases of Chronic Heart Failure with Arrhythmia with Qi and Yin Deficiency Syndrome: a Clinical Observation

Related Author

WANG Xianliang

ZHANG Jingyi

GE Zhao

LIU Tongzuo

ZHANG Maozhe

WANG Shuai

ZHAO Zhiqiang

BI Yingfei

Related Institution

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/ National Clinical Research Center for Chinese Medicine

Tianjin University of Traditional Chinese Medicine

First Teaching Hospital of Tianjin University of Traditional Chinese Medicine/National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion

The First Affiliated Hospital of Henan University of Chinese Medicine

Taihe Hospital of Traditional Chinese Medicine，Anhui University of Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰